Analyst Ratings For Concert Pharmaceuticals (NASDAQ:CNCE)
Today, HC Wainwright initiated coverage on Concert Pharmaceuticals (NASDAQ:CNCE) with a Buy with a price target of $20.00.
There are 5 buy ratings on the stock.
The current consensus rating on Concert Pharmaceuticals (NASDAQ:CNCE) is Buy (Score: 3.00) with a consensus target price of $26.40 per share, a potential 88.17% upside.
Some recent analyst ratings include
- 7/24/2017-HC Wainwright initiated coverage with a Buy rating.
- 7/10/2017-Stifel Nicolaus Reiterated Rating of Buy.
- 6/12/2017-Aegis Reiterated Rating of Buy.
- 9/7/2016-Brean Capital Reiterated Rating of Buy.
Recent Insider Trading Activity For Concert Pharmaceuticals (NASDAQ:CNCE)
Concert Pharmaceuticals (NASDAQ:CNCE) has insider ownership of 15.30% and institutional ownership of 62.80%.
- On 5/12/2016 Thomas G Auchincloss, Director, bought 2,000 with an average share price of $10.11 per share and the total transaction amounting to $20,220.00. View SEC Filing
- On 5/11/2016 Roger D Tung, CEO, bought 19,610 with an average share price of $10.55 per share and the total transaction amounting to $206,885.50. View SEC Filing
- On 12/16/2015 Wilfred E Jaeger, Director, sold 10,360 with an average share price of $19.57 per share and the total transaction amounting to $202,745.20. View SEC Filing
- On 12/15/2015 Wilfred E Jaeger, Director, sold 54,572 with an average share price of $20.10 per share and the total transaction amounting to $1,096,897.20. View SEC Filing
- On 12/14/2015 Pauline Mcgowan, VP, sold 498 with an average share price of $20.07 per share and the total transaction amounting to $9,994.86. View SEC Filing
- On 12/14/2015 Wilfred E Jaeger, Director, sold 3,922 with an average share price of $20.09 per share and the total transaction amounting to $78,792.98. View SEC Filing
- On 11/9/2015 Ronald W. Barrett, Director, sold 17,699 with an average share price of $22.27 per share and the total transaction amounting to $394,156.73. View SEC Filing
Recent Trading Activity for Concert Pharmaceuticals (NASDAQ:CNCE)
Shares of Concert Pharmaceuticals closed the previous trading session at 14.03 down -0.23 -1.61% with 101,739 shares trading hands.